No Data
Express News | Iteos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 a2a-005 Clinical Trial Data in 2L Nsclc at Esmo Immuno-Oncology Congress
ITeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
We're Keeping An Eye On ITeos Therapeutics' (NASDAQ:ITOS) Cash Burn Rate
ITeos Therapeutics Down Over 29%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
ITeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Market-Moving News for September 16th
No Data
No Data